Literature DB >> 16339528

Identification of specific proteins and peptides in Mycobacterium leprae suitable for the selective diagnosis of leprosy.

John S Spencer1, Hazel M Dockrell, Hee Jin Kim, Maria A M Marques, Diana L Williams, Marcia V S B Martins, Marcio L F Martins, Monica C B S Lima, Euzenir N Sarno, Geraldo M B Pereira, Haroldo Matos, Leila S Fonseca, Elisabeth P Sampaio, Thomas H M Ottenhoff, Annemieke Geluk, Sang-Nae Cho, Neil G Stoker, Stewart T Cole, Patrick J Brennan, Maria C V Pessolani.   

Abstract

Diagnosis of leprosy is a major obstacle to disease control and has been compromised in the past due to the lack of specific reagents. We have used comparative genome analysis to identify genes that are specific to Mycobacterium leprae and tested both recombinant proteins and synthetic peptides from a subset of these for immunological reactivity. Four unique recombinant proteins (ML0008, ML0126, ML1057, and ML2567) and a panel of 58 peptides (15 and 9 mer) were tested for IFN-gamma responses in PBMC from leprosy patients and contacts, tuberculosis patients, and endemic and nonendemic controls. The responses to the four recombinant proteins gave higher levels of IFN-gamma production, but less specificity, than the peptides. Thirty-five peptides showed IFN-gamma responses only in the paucibacillary leprosy and household contact groups, with no responses in the tuberculosis or endemic control groups. High frequencies of IFN-gamma-producing CD4+ and CD8+ T cells specific for the 15- and 9-mer peptides were observed in the blood of a paucibacillary leprosy patient. 9-mer peptides preferentially activated CD8+ T cells, while the 15-mer peptides were efficient in inducing responses in both the CD4+ and CD8+ T cell subsets. Four of the six 9-mer peptides tested showed promising specificity, indicating that CD8+ T cell epitopes may also have diagnostic potential. Those peptides that provide specific responses in leprosy patients from an endemic setting could potentially be developed into a rapid diagnostic test for the early detection of M. leprae infection and epidemiological surveys of the incidence of leprosy, of which little is known.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16339528     DOI: 10.4049/jimmunol.175.12.7930

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

1.  Lsr2 peptides of Mycobacterium leprae show hierarchical responses in lymphoproliferative assays, with selective recognition by patients with anergic lepromatous leprosy.

Authors:  Mehervani Chaduvula; A Murtaza; Namita Misra; N P Shankar Narayan; V Ramesh; H K Prasad; Rajni Rani; R K Chinnadurai; Indira Nath
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

2.  Evaluation of various cytokines elicited during antigen-specific recall as potential risk indicators for the differential development of leprosy.

Authors:  L H Sampaio; A L M Sousa; M C Barcelos; S G Reed; M M A Stefani; M S Duthie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-12       Impact factor: 3.267

Review 3.  Mycobacterium leprae-host-cell interactions and genetic determinants in leprosy: an overview.

Authors:  Roberta Olmo Pinheiro; Jorgenilce de Souza Salles; Euzenir Nunes Sarno; Elizabeth Pereira Sampaio
Journal:  Future Microbiol       Date:  2011-02       Impact factor: 3.165

4.  Defining mycobacteria: Shared and specific genome features for different lifestyles.

Authors:  Varalakshmi D Vissa; Rama Murthy Sakamuri; Wei Li; Patrick J Brennan
Journal:  Indian J Microbiol       Date:  2009-02-05       Impact factor: 2.461

5.  ML1419c peptide immunization induces Mycobacterium leprae-specific HLA-A*0201-restricted CTL in vivo with potential to kill live mycobacteria.

Authors:  Annemieke Geluk; Susan J F van den Eeden; Karin Dijkman; Louis Wilson; Hee Jin Kim; Kees L M C Franken; John S Spencer; Maria C V Pessolani; Geraldo M B Pereira; Tom H M Ottenhoff
Journal:  J Immunol       Date:  2011-06-24       Impact factor: 5.422

6.  Synergistic antigen combinations for the development of interferon gamma release assays for paucibacillary leprosy.

Authors:  R M Oliveira; E M Hungria; A de Araújo Freitas; A L O M de Sousa; M B Costa; S G Reed; M S Duthie; M M A Stefani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-03-12       Impact factor: 3.267

7.  From genome-based in silico predictions to ex vivo verification of leprosy diagnosis.

Authors:  Annemieke Geluk; John S Spencer; Kidist Bobosha; Maria C V Pessolani; Geraldo M B Pereira; Sayera Banu; Nadine Honoré; Stephen T Reece; Murdo MacDonald; Bishwa Raj Sapkota; Chaman Ranjit; Kees L M C Franken; Martha Zewdie; Abraham Aseffa; Rabia Hussain; Mariane M Stefani; Sang-Nae Cho; Linda Oskam; Patrick J Brennan; Hazel M Dockrell
Journal:  Clin Vaccine Immunol       Date:  2009-01-28

8.  Risk and protective factors for leprosy development determined by epidemiological surveillance of household contacts.

Authors:  Isabela M B Goulart; Dulcinéa O Bernardes Souza; Carolina R Marques; Vânia L Pimenta; Maria A Gonçalves; Luiz R Goulart
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

9.  Diguanylate cyclase activity of the Mycobacterium leprae T cell antigen ML1419c.

Authors:  Suwatchareeporn Rotcheewaphan; John T Belisle; Kristofor J Webb; Hee-Jin Kim; John S Spencer; Bradley R Borlee
Journal:  Microbiology (Reading)       Date:  2016-07-22       Impact factor: 2.777

10.  Antigen-specific T-cell responses of leprosy patients.

Authors:  Malcolm S Duthie; Wakako Goto; Greg C Ireton; Stephen T Reece; Lucas H Sampaio; A B Grassi; Ana Lucia M Sousa; Celina M T Martelli; Mariane M A Stefani; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2008-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.